SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: E. Todd Phillips who wrote (551)4/5/1998 4:28:00 PM
From: yosi s  Read Replies (1) of 1491
 
We are getting ahead of ourselves in this thread.

For pars tamoxiphen analoge to get designation for breast cancer prevention will take long years.

They first got to get through phase 1
Yes it has that potential.

But right now HU211 is in late phase 2 (2-3 yrs ahead of tamoxiphen).
yet hu211 is completely discounted in the value of PARS.
If PARS was Merck yes than credit be there.

But all in all Pars version of tamoxiphen may have that indication if it is effective and safer as theoretically it seems.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News